Administration of Brincidofovir and Convalescent Plasma in a Patient with Ebola Virus Disease

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 969-973

  Florescu, Diana F ^a,b   Kalil, Andre C ^a   Hewlett, Angela L ^a   Schuh, Amy J ^c   Stroher, Ute ^c   Uyeki, Timothy M ^d   Smith, Philip W ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Ebola; investigational therapies; trials

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ARTEMETHER PLUS BENFLUMETOL; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILIRUBIN; BRINCIDOFOVIR; CALCIUM; CEFIXIME; CHLORIDE; CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFUSION FLUID; INTRALIPID; LOPERAMIDE; MAGNESIUM; MAGNESIUM SULFATE; METOCLOPRAMIDE; ONDANSETRON; POTASSIUM CHLORIDE; RINGER LACTATE SOLUTION; SODIUM; ANTIVIRUS AGENT; CYTOSINE; PHOSPHONIC ACID DERIVATIVE; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ANOREXIA; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; BLOOD PRESSURE CUFF; BLOOD PRESSURE MEASUREMENT; BODY TEMPERATURE; BRADYCARDIA; CASE REPORT; CENTRAL VENOUS CATHETER; CHILL; CONJUNCTIVITIS; CONVALESCENT PLASMA; COUGHING; DECREASED APPETITE; DIARRHEA; DYSPNEA; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL THERAPY; FATIGUE; FEVER; HEADACHE; HEMATOCRIT; HOSPITAL ADMISSION; HUMAN; HYDRATION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNE RESPONSE; INTERNATIONAL NORMALIZED RATIO; INTESTINE SOUND; KIDNEY FUNCTION; LABORATORY TEST; LEUKOCYTOSIS; LEUKOPENIA; LUNG EDEMA; MALAISE; MALARIA; MALE; MIXED INFECTION; MYALGIA; NAUSEA; NEUTROPHILIA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT TRANSPORT; PHYSICAL EXAMINATION; PLASMA; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOTAL PARENTERAL NUTRITION; TREMOR; URINE VOLUME; VIRUS LOAD; VOMITING; WEAKNESS; AFRICA; ANALOGS AND DERIVATIVES; BLOOD; HEMORRHAGIC FEVER, EBOLA; LEUKOCYTE COUNT; PASSIVE IMMUNIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; AFRICA, WESTERN; ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CYTOSINE; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKOCYTE COUNT; MALE; ORGANOPHOSPHONATES; PLASMA; PLATELET COUNT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84940659400     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ395     Document Type: Article

References (21)

1. World Health Organization. Ebola situation report. Available at: http://apps.who.int/ebola/en/ebola-situation-reports. Accessed 6 May 2015.
2. World Health Organization. Potential Ebola therapies and vaccines. Available at: http://www.who.int/csr/resources/publications/ebola/potential-therapies-vaccines/en/. Accessed 30 November 2014.
3. Goodman JL. Studying "secret serums"-toward safe, effective Ebola treatments. N Engl J Med 2014; 371:1086-9.
4. Onyango CO, Opoka ML, Ksiazek TG, et al. Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan, 2004. J Infect Dis 2007; 196(suppl 2):S193-8.
5. Towner JS, Sealy TK, Ksiazek TG, Nichol ST. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007; 196(suppl 2):S205-12.
6. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J 1977; 2:541-4.
7. Lyon GM, Mehta AK, Varkey JB, et al; Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; 371:2402-9.
8. Schieffelin JS, Shaffer JG, Goba A, et al; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014; 371:2092-100.
9. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa-clinical manifestations and management. N Engl J Med 2014; 371:2054-7.
10. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(suppl 1):S18-23.
11. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196(suppl 2):S400-3.
12. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(suppl 1):S224-34.
13. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 1999; 179(suppl 1): S218-23.
14. Becquart P, Mahlakoiv T, Nkoghe D, Leroy EM. Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. PLoS One 2014; 9:e96360.
15. Sobarzo A, Groseth A, Dolnik O, et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 2013; 208:299-309.
16. Sobarzo A, Perelman E, Groseth A, et al. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay. Clin Vaccine Immunol 2012; 19:1844-52.
17. Whelan SP, Barr JN, Wertz GW. Transcription and replication of nonsegmented negative-strand RNA viruses. Curr Top Microbiol Immunol 2004; 283:61-119.
18. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56:2726-34.
19. Florescu DF, Keck MA. Development of CMX001 (brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti Infect Ther 2014; 12:1171-8.
20. Marty FM,Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369:1227-36.
21. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2000; 12:397-408.